nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ABCB1—ovarian cancer	0.414	1	CbGaD
Maprotiline—ABCB1—Topotecan—ovarian cancer	0.0354	0.267	CbGbCtD
Maprotiline—ABCB1—Vinorelbine—ovarian cancer	0.0249	0.188	CbGbCtD
Maprotiline—CYP2D6—Vinorelbine—ovarian cancer	0.0235	0.178	CbGbCtD
Maprotiline—ABCB1—Paclitaxel—ovarian cancer	0.0175	0.132	CbGbCtD
Maprotiline—CHRM3—muscle of abdomen—ovarian cancer	0.0133	0.164	CbGeAlD
Maprotiline—ABCB1—Docetaxel—ovarian cancer	0.0127	0.0957	CbGbCtD
Maprotiline—HTR7—vein—ovarian cancer	0.00972	0.12	CbGeAlD
Maprotiline—ABCB1—Doxorubicin—ovarian cancer	0.00945	0.0714	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—ovarian cancer	0.0089	0.0672	CbGbCtD
Maprotiline—HTR2A—vein—ovarian cancer	0.00606	0.0749	CbGeAlD
Maprotiline—CHRM5—epithelium—ovarian cancer	0.00282	0.0349	CbGeAlD
Maprotiline—CHRM4—testis—ovarian cancer	0.00216	0.0267	CbGeAlD
Maprotiline—ORM1—endometrium—ovarian cancer	0.00186	0.023	CbGeAlD
Maprotiline—ORM1—female reproductive system—ovarian cancer	0.00154	0.0191	CbGeAlD
Maprotiline—HTR7—epithelium—ovarian cancer	0.0015	0.0186	CbGeAlD
Maprotiline—SLC6A2—decidua—ovarian cancer	0.00147	0.0182	CbGeAlD
Maprotiline—ORM1—bone marrow—ovarian cancer	0.00146	0.018	CbGeAlD
Maprotiline—HRH1—myometrium—ovarian cancer	0.00143	0.0176	CbGeAlD
Maprotiline—HTR2C—female reproductive system—ovarian cancer	0.00139	0.0171	CbGeAlD
Maprotiline—CHRM1—female reproductive system—ovarian cancer	0.00131	0.0162	CbGeAlD
Maprotiline—SLC6A2—gonad—ovarian cancer	0.0013	0.016	CbGeAlD
Maprotiline—HTR7—gonad—ovarian cancer	0.00125	0.0154	CbGeAlD
Maprotiline—CHRM3—female reproductive system—ovarian cancer	0.00117	0.0145	CbGeAlD
Maprotiline—SLC6A3—testis—ovarian cancer	0.00116	0.0143	CbGeAlD
Maprotiline—SLC6A2—female reproductive system—ovarian cancer	0.00116	0.0143	CbGeAlD
Maprotiline—HTR2A—embryo—ovarian cancer	0.00115	0.0142	CbGeAlD
Maprotiline—HRH1—epithelium—ovarian cancer	0.00112	0.0139	CbGeAlD
Maprotiline—HTR7—female reproductive system—ovarian cancer	0.00112	0.0138	CbGeAlD
Maprotiline—HRH1—uterine cervix—ovarian cancer	0.00111	0.0137	CbGeAlD
Maprotiline—CHRM3—female gonad—ovarian cancer	0.00107	0.0132	CbGeAlD
Maprotiline—HRH1—decidua—ovarian cancer	0.00106	0.0131	CbGeAlD
Maprotiline—HRH1—endometrium—ovarian cancer	0.00101	0.0124	CbGeAlD
Maprotiline—CHRM3—testis—ovarian cancer	0.000946	0.0117	CbGeAlD
Maprotiline—HTR2A—epithelium—ovarian cancer	0.000937	0.0116	CbGeAlD
Maprotiline—SLC6A2—testis—ovarian cancer	0.000934	0.0115	CbGeAlD
Maprotiline—Sertraline—ABCB1—ovarian cancer	0.00093	0.524	CrCbGaD
Maprotiline—ORM1—lymph node—ovarian cancer	0.000903	0.0112	CbGeAlD
Maprotiline—HTR7—testis—ovarian cancer	0.0009	0.0111	CbGeAlD
Maprotiline—DRD2—testis—ovarian cancer	0.000851	0.0105	CbGeAlD
Maprotiline—HRH1—female reproductive system—ovarian cancer	0.000833	0.0103	CbGeAlD
Maprotiline—ABCB1—myometrium—ovarian cancer	0.000782	0.00966	CbGeAlD
Maprotiline—HTR2A—gonad—ovarian cancer	0.000779	0.00962	CbGeAlD
Maprotiline—HRH1—female gonad—ovarian cancer	0.000758	0.00936	CbGeAlD
Maprotiline—HRH1—vagina—ovarian cancer	0.000753	0.00931	CbGeAlD
Maprotiline—ABCB1—embryo—ovarian cancer	0.000752	0.00929	CbGeAlD
Maprotiline—HTR2A—female reproductive system—ovarian cancer	0.000696	0.00859	CbGeAlD
Maprotiline—SLC6A2—lymph node—ovarian cancer	0.000677	0.00836	CbGeAlD
Maprotiline—HRH1—testis—ovarian cancer	0.000672	0.0083	CbGeAlD
Maprotiline—CYP2D6—female reproductive system—ovarian cancer	0.000634	0.00783	CbGeAlD
Maprotiline—HTR2A—vagina—ovarian cancer	0.000629	0.00777	CbGeAlD
Maprotiline—ABCB1—epithelium—ovarian cancer	0.000614	0.00758	CbGeAlD
Maprotiline—ABCB1—uterine cervix—ovarian cancer	0.000609	0.00752	CbGeAlD
Maprotiline—ABCB1—decidua—ovarian cancer	0.00058	0.00716	CbGeAlD
Maprotiline—CYP2D6—female gonad—ovarian cancer	0.000577	0.00712	CbGeAlD
Maprotiline—HTR2A—testis—ovarian cancer	0.000562	0.00694	CbGeAlD
Maprotiline—ABCB1—endometrium—ovarian cancer	0.00055	0.0068	CbGeAlD
Maprotiline—Protriptyline—ABCB1—ovarian cancer	0.000534	0.301	CrCbGaD
Maprotiline—CYP2D6—testis—ovarian cancer	0.000512	0.00632	CbGeAlD
Maprotiline—ABCB1—gonad—ovarian cancer	0.000511	0.00631	CbGeAlD
Maprotiline—ABCB1—uterus—ovarian cancer	0.000507	0.00626	CbGeAlD
Maprotiline—HRH1—lymph node—ovarian cancer	0.000487	0.00602	CbGeAlD
Maprotiline—ABCB1—female reproductive system—ovarian cancer	0.000456	0.00563	CbGeAlD
Maprotiline—ABCB1—bone marrow—ovarian cancer	0.00043	0.00532	CbGeAlD
Maprotiline—ABCB1—female gonad—ovarian cancer	0.000415	0.00512	CbGeAlD
Maprotiline—ABCB1—vagina—ovarian cancer	0.000412	0.00509	CbGeAlD
Maprotiline—Rash—Melphalan—ovarian cancer	0.00038	0.00116	CcSEcCtD
Maprotiline—Dermatitis—Melphalan—ovarian cancer	0.00038	0.00116	CcSEcCtD
Maprotiline—Asthenia—Vinorelbine—ovarian cancer	0.000378	0.00116	CcSEcCtD
Maprotiline—Arrhythmia—Docetaxel—ovarian cancer	0.000378	0.00116	CcSEcCtD
Maprotiline—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000377	0.00115	CcSEcCtD
Maprotiline—Convulsion—Paclitaxel—ovarian cancer	0.000376	0.00115	CcSEcCtD
Maprotiline—Hypertension—Paclitaxel—ovarian cancer	0.000375	0.00115	CcSEcCtD
Maprotiline—Alopecia—Docetaxel—ovarian cancer	0.000374	0.00114	CcSEcCtD
Maprotiline—Pruritus—Vinorelbine—ovarian cancer	0.000373	0.00114	CcSEcCtD
Maprotiline—Breast disorder—Epirubicin—ovarian cancer	0.000373	0.00114	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000371	0.00114	CcSEcCtD
Maprotiline—Anxiety—Paclitaxel—ovarian cancer	0.000368	0.00113	CcSEcCtD
Maprotiline—Malnutrition—Docetaxel—ovarian cancer	0.000368	0.00113	CcSEcCtD
Maprotiline—ABCB1—testis—ovarian cancer	0.000368	0.00455	CbGeAlD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000367	0.00112	CcSEcCtD
Maprotiline—Nausea—Topotecan—ovarian cancer	0.000366	0.00112	CcSEcCtD
Maprotiline—Muscular weakness—Epirubicin—ovarian cancer	0.000364	0.00111	CcSEcCtD
Maprotiline—Dry mouth—Paclitaxel—ovarian cancer	0.000362	0.00111	CcSEcCtD
Maprotiline—Diarrhoea—Vinorelbine—ovarian cancer	0.000361	0.0011	CcSEcCtD
Maprotiline—Dysgeusia—Docetaxel—ovarian cancer	0.00036	0.0011	CcSEcCtD
Maprotiline—Ataxia—Doxorubicin—ovarian cancer	0.000359	0.0011	CcSEcCtD
Maprotiline—Nausea—Melphalan—ovarian cancer	0.000358	0.0011	CcSEcCtD
Maprotiline—Confusional state—Paclitaxel—ovarian cancer	0.000357	0.00109	CcSEcCtD
Maprotiline—Dysphagia—Epirubicin—ovarian cancer	0.000356	0.00109	CcSEcCtD
Maprotiline—Oedema—Paclitaxel—ovarian cancer	0.000354	0.00109	CcSEcCtD
Maprotiline—Eosinophilia—Epirubicin—ovarian cancer	0.000353	0.00108	CcSEcCtD
Maprotiline—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000352	0.00108	CcSEcCtD
Maprotiline—Infection—Paclitaxel—ovarian cancer	0.000352	0.00108	CcSEcCtD
Maprotiline—Shock—Paclitaxel—ovarian cancer	0.000349	0.00107	CcSEcCtD
Maprotiline—Dizziness—Vinorelbine—ovarian cancer	0.000348	0.00107	CcSEcCtD
Maprotiline—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000348	0.00107	CcSEcCtD
Maprotiline—Nervous system disorder—Paclitaxel—ovarian cancer	0.000348	0.00106	CcSEcCtD
Maprotiline—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000347	0.00106	CcSEcCtD
Maprotiline—Tachycardia—Paclitaxel—ovarian cancer	0.000346	0.00106	CcSEcCtD
Maprotiline—Breast disorder—Doxorubicin—ovarian cancer	0.000345	0.00106	CcSEcCtD
Maprotiline—Skin disorder—Paclitaxel—ovarian cancer	0.000344	0.00105	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000343	0.00105	CcSEcCtD
Maprotiline—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000343	0.00105	CcSEcCtD
Maprotiline—Pancytopenia—Epirubicin—ovarian cancer	0.000338	0.00104	CcSEcCtD
Maprotiline—Muscular weakness—Doxorubicin—ovarian cancer	0.000336	0.00103	CcSEcCtD
Maprotiline—Vomiting—Vinorelbine—ovarian cancer	0.000335	0.00103	CcSEcCtD
Maprotiline—Rash—Vinorelbine—ovarian cancer	0.000332	0.00102	CcSEcCtD
Maprotiline—Dermatitis—Vinorelbine—ovarian cancer	0.000332	0.00102	CcSEcCtD
Maprotiline—Hypotension—Paclitaxel—ovarian cancer	0.000331	0.00101	CcSEcCtD
Maprotiline—Headache—Vinorelbine—ovarian cancer	0.00033	0.00101	CcSEcCtD
Maprotiline—Syncope—Docetaxel—ovarian cancer	0.00033	0.00101	CcSEcCtD
Maprotiline—Dysphagia—Doxorubicin—ovarian cancer	0.00033	0.00101	CcSEcCtD
Maprotiline—Leukopenia—Docetaxel—ovarian cancer	0.000329	0.00101	CcSEcCtD
Maprotiline—Pollakiuria—Epirubicin—ovarian cancer	0.000329	0.00101	CcSEcCtD
Maprotiline—Eosinophilia—Doxorubicin—ovarian cancer	0.000326	0.000999	CcSEcCtD
Maprotiline—Palpitations—Docetaxel—ovarian cancer	0.000325	0.000996	CcSEcCtD
Maprotiline—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000325	0.000996	CcSEcCtD
Maprotiline—Weight increased—Epirubicin—ovarian cancer	0.000324	0.000993	CcSEcCtD
Maprotiline—Loss of consciousness—Docetaxel—ovarian cancer	0.000324	0.000991	CcSEcCtD
Maprotiline—Weight decreased—Epirubicin—ovarian cancer	0.000322	0.000987	CcSEcCtD
Maprotiline—Insomnia—Paclitaxel—ovarian cancer	0.000321	0.000981	CcSEcCtD
Maprotiline—Convulsion—Docetaxel—ovarian cancer	0.000319	0.000976	CcSEcCtD
Maprotiline—Paraesthesia—Paclitaxel—ovarian cancer	0.000318	0.000974	CcSEcCtD
Maprotiline—Hypertension—Docetaxel—ovarian cancer	0.000318	0.000973	CcSEcCtD
Maprotiline—Infestation—Epirubicin—ovarian cancer	0.000318	0.000973	CcSEcCtD
Maprotiline—Drowsiness—Epirubicin—ovarian cancer	0.000318	0.000973	CcSEcCtD
Maprotiline—Infestation NOS—Epirubicin—ovarian cancer	0.000318	0.000973	CcSEcCtD
Maprotiline—Somnolence—Paclitaxel—ovarian cancer	0.000315	0.000965	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000315	0.000964	CcSEcCtD
Maprotiline—Pancytopenia—Doxorubicin—ovarian cancer	0.000313	0.000959	CcSEcCtD
Maprotiline—Nausea—Vinorelbine—ovarian cancer	0.000313	0.000958	CcSEcCtD
Maprotiline—Dyspepsia—Paclitaxel—ovarian cancer	0.000312	0.000955	CcSEcCtD
Maprotiline—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000311	0.000953	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000311	0.000953	CcSEcCtD
Maprotiline—Stomatitis—Epirubicin—ovarian cancer	0.00031	0.000948	CcSEcCtD
Maprotiline—Jaundice—Epirubicin—ovarian cancer	0.00031	0.000948	CcSEcCtD
Maprotiline—Dry mouth—Docetaxel—ovarian cancer	0.000306	0.000938	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000306	0.000937	CcSEcCtD
Maprotiline—Fatigue—Paclitaxel—ovarian cancer	0.000306	0.000936	CcSEcCtD
Maprotiline—Pollakiuria—Doxorubicin—ovarian cancer	0.000305	0.000933	CcSEcCtD
Maprotiline—Constipation—Paclitaxel—ovarian cancer	0.000303	0.000928	CcSEcCtD
Maprotiline—Confusional state—Docetaxel—ovarian cancer	0.000303	0.000927	CcSEcCtD
Maprotiline—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000301	0.000921	CcSEcCtD
Maprotiline—Hepatobiliary disease—Epirubicin—ovarian cancer	0.0003	0.00092	CcSEcCtD
Maprotiline—Oedema—Docetaxel—ovarian cancer	0.0003	0.00092	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—ovarian cancer	0.0003	0.000919	CcSEcCtD
Maprotiline—Infection—Docetaxel—ovarian cancer	0.000298	0.000914	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—ovarian cancer	0.000298	0.000913	CcSEcCtD
Maprotiline—Agranulocytosis—Epirubicin—ovarian cancer	0.000296	0.000908	CcSEcCtD
Maprotiline—Shock—Docetaxel—ovarian cancer	0.000296	0.000905	CcSEcCtD
Maprotiline—Nervous system disorder—Docetaxel—ovarian cancer	0.000295	0.000902	CcSEcCtD
Maprotiline—Thrombocytopenia—Docetaxel—ovarian cancer	0.000294	0.000901	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—ovarian cancer	0.000294	0.0009	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—ovarian cancer	0.000294	0.0009	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—ovarian cancer	0.000294	0.0009	CcSEcCtD
Maprotiline—Tachycardia—Docetaxel—ovarian cancer	0.000293	0.000898	CcSEcCtD
Maprotiline—Feeling abnormal—Paclitaxel—ovarian cancer	0.000292	0.000894	CcSEcCtD
Maprotiline—Skin disorder—Docetaxel—ovarian cancer	0.000292	0.000893	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000291	0.000892	CcSEcCtD
Maprotiline—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00029	0.000887	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000288	0.000882	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—ovarian cancer	0.000287	0.000877	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—ovarian cancer	0.000287	0.000877	CcSEcCtD
Maprotiline—Hepatitis—Epirubicin—ovarian cancer	0.000285	0.000873	CcSEcCtD
Maprotiline—Hypoaesthesia—Epirubicin—ovarian cancer	0.000284	0.000869	CcSEcCtD
Maprotiline—Urinary tract disorder—Epirubicin—ovarian cancer	0.000282	0.000862	CcSEcCtD
Maprotiline—Urticaria—Paclitaxel—ovarian cancer	0.000282	0.000862	CcSEcCtD
Maprotiline—Hypotension—Docetaxel—ovarian cancer	0.000281	0.000859	CcSEcCtD
Maprotiline—Abdominal pain—Paclitaxel—ovarian cancer	0.00028	0.000858	CcSEcCtD
Maprotiline—Body temperature increased—Paclitaxel—ovarian cancer	0.00028	0.000858	CcSEcCtD
Maprotiline—Urethral disorder—Epirubicin—ovarian cancer	0.00028	0.000856	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000278	0.000851	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—ovarian cancer	0.000274	0.00084	CcSEcCtD
Maprotiline—Insomnia—Docetaxel—ovarian cancer	0.000272	0.000832	CcSEcCtD
Maprotiline—Paraesthesia—Docetaxel—ovarian cancer	0.00027	0.000826	CcSEcCtD
Maprotiline—Erythema multiforme—Epirubicin—ovarian cancer	0.00027	0.000826	CcSEcCtD
Maprotiline—Somnolence—Docetaxel—ovarian cancer	0.000267	0.000818	CcSEcCtD
Maprotiline—ABCB1—lymph node—ovarian cancer	0.000267	0.00329	CbGeAlD
Maprotiline—Eye disorder—Epirubicin—ovarian cancer	0.000267	0.000816	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—ovarian cancer	0.000266	0.000814	CcSEcCtD
Maprotiline—Flushing—Epirubicin—ovarian cancer	0.000265	0.00081	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—ovarian cancer	0.000265	0.00081	CcSEcCtD
Maprotiline—Dyspepsia—Docetaxel—ovarian cancer	0.000264	0.00081	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—ovarian cancer	0.000264	0.000808	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000263	0.000804	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000261	0.000798	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000259	0.000794	CcSEcCtD
Maprotiline—Fatigue—Docetaxel—ovarian cancer	0.000259	0.000793	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—ovarian cancer	0.000259	0.000792	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—ovarian cancer	0.000259	0.000792	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—ovarian cancer	0.000257	0.000787	CcSEcCtD
Maprotiline—Constipation—Docetaxel—ovarian cancer	0.000257	0.000787	CcSEcCtD
Maprotiline—Arrhythmia—Epirubicin—ovarian cancer	0.000255	0.00078	CcSEcCtD
Maprotiline—Asthenia—Paclitaxel—ovarian cancer	0.000254	0.000779	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—ovarian cancer	0.000252	0.000772	CcSEcCtD
Maprotiline—Pruritus—Paclitaxel—ovarian cancer	0.000251	0.000768	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—ovarian cancer	0.00025	0.000764	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—ovarian cancer	0.000248	0.00076	CcSEcCtD
Maprotiline—Feeling abnormal—Docetaxel—ovarian cancer	0.000248	0.000758	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—ovarian cancer	0.000247	0.000755	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—ovarian cancer	0.000246	0.000753	CcSEcCtD
Maprotiline—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000246	0.000752	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—ovarian cancer	0.000245	0.00075	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—ovarian cancer	0.000245	0.00075	CcSEcCtD
Maprotiline—Tension—Epirubicin—ovarian cancer	0.000244	0.000746	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—ovarian cancer	0.000243	0.000744	CcSEcCtD
Maprotiline—Diarrhoea—Paclitaxel—ovarian cancer	0.000242	0.000742	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—ovarian cancer	0.000241	0.000738	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—ovarian cancer	0.000239	0.000733	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000238	0.000728	CcSEcCtD
Maprotiline—Abdominal pain—Docetaxel—ovarian cancer	0.000237	0.000727	CcSEcCtD
Maprotiline—Body temperature increased—Docetaxel—ovarian cancer	0.000237	0.000727	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—ovarian cancer	0.000236	0.000722	CcSEcCtD
Maprotiline—Dizziness—Paclitaxel—ovarian cancer	0.000234	0.000718	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—ovarian cancer	0.000234	0.000716	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—ovarian cancer	0.000233	0.000714	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—ovarian cancer	0.00023	0.000703	CcSEcCtD
Maprotiline—Agitation—Epirubicin—ovarian cancer	0.000228	0.000699	CcSEcCtD
Maprotiline—Tension—Doxorubicin—ovarian cancer	0.000225	0.00069	CcSEcCtD
Maprotiline—Vomiting—Paclitaxel—ovarian cancer	0.000225	0.00069	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—ovarian cancer	0.000225	0.000689	CcSEcCtD
Maprotiline—Rash—Paclitaxel—ovarian cancer	0.000223	0.000684	CcSEcCtD
Maprotiline—Dermatitis—Paclitaxel—ovarian cancer	0.000223	0.000684	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—ovarian cancer	0.000223	0.000683	CcSEcCtD
Maprotiline—Syncope—Epirubicin—ovarian cancer	0.000223	0.000682	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—ovarian cancer	0.000222	0.00068	CcSEcCtD
Maprotiline—Headache—Paclitaxel—ovarian cancer	0.000222	0.00068	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—ovarian cancer	0.000219	0.000672	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—ovarian cancer	0.000218	0.000668	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—ovarian cancer	0.000216	0.000663	CcSEcCtD
Maprotiline—Asthenia—Docetaxel—ovarian cancer	0.000216	0.00066	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—ovarian cancer	0.000215	0.000659	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—ovarian cancer	0.000214	0.000656	CcSEcCtD
Maprotiline—Pruritus—Docetaxel—ovarian cancer	0.000213	0.000651	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—ovarian cancer	0.000211	0.000646	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—ovarian cancer	0.000211	0.000645	CcSEcCtD
Maprotiline—Nausea—Paclitaxel—ovarian cancer	0.000211	0.000645	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00021	0.000643	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—ovarian cancer	0.000207	0.000633	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—ovarian cancer	0.000206	0.000631	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—ovarian cancer	0.000206	0.00063	CcSEcCtD
Maprotiline—Diarrhoea—Docetaxel—ovarian cancer	0.000206	0.000629	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—ovarian cancer	0.000204	0.000626	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—ovarian cancer	0.000203	0.000622	CcSEcCtD
Maprotiline—Oedema—Epirubicin—ovarian cancer	0.000203	0.00062	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—ovarian cancer	0.000202	0.000618	CcSEcCtD
Maprotiline—Infection—Epirubicin—ovarian cancer	0.000201	0.000616	CcSEcCtD
Maprotiline—Shock—Epirubicin—ovarian cancer	0.000199	0.00061	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—ovarian cancer	0.000199	0.000609	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—ovarian cancer	0.000199	0.000608	CcSEcCtD
Maprotiline—Dizziness—Docetaxel—ovarian cancer	0.000199	0.000608	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—ovarian cancer	0.000198	0.000607	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—ovarian cancer	0.000198	0.000607	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—ovarian cancer	0.000198	0.000605	CcSEcCtD
Maprotiline—Skin disorder—Epirubicin—ovarian cancer	0.000197	0.000603	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—ovarian cancer	0.000196	0.0006	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—ovarian cancer	0.000195	0.000597	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000194	0.000595	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—ovarian cancer	0.000191	0.000586	CcSEcCtD
Maprotiline—Vomiting—Docetaxel—ovarian cancer	0.000191	0.000585	CcSEcCtD
Maprotiline—Rash—Docetaxel—ovarian cancer	0.000189	0.00058	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—ovarian cancer	0.000189	0.00058	CcSEcCtD
Maprotiline—Dermatitis—Docetaxel—ovarian cancer	0.000189	0.000579	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—ovarian cancer	0.000189	0.000579	CcSEcCtD
Maprotiline—Headache—Docetaxel—ovarian cancer	0.000188	0.000576	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—ovarian cancer	0.000187	0.000574	CcSEcCtD
Maprotiline—Infection—Doxorubicin—ovarian cancer	0.000186	0.00057	CcSEcCtD
Maprotiline—Shock—Doxorubicin—ovarian cancer	0.000184	0.000565	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—ovarian cancer	0.000184	0.000563	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000184	0.000562	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—ovarian cancer	0.000183	0.000561	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—ovarian cancer	0.000183	0.00056	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—ovarian cancer	0.000182	0.000558	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—ovarian cancer	0.000182	0.000557	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000181	0.000555	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—ovarian cancer	0.00018	0.000552	CcSEcCtD
Maprotiline—Nausea—Docetaxel—ovarian cancer	0.000178	0.000546	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—ovarian cancer	0.000178	0.000546	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—ovarian cancer	0.000175	0.000536	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000175	0.000536	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—ovarian cancer	0.000175	0.000535	CcSEcCtD
Maprotiline—Constipation—Epirubicin—ovarian cancer	0.000173	0.000531	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—ovarian cancer	0.00017	0.000519	CcSEcCtD
Maprotiline—Desipramine—ABCB1—ovarian cancer	0.000168	0.0949	CrCbGaD
Maprotiline—Paraesthesia—Doxorubicin—ovarian cancer	0.000168	0.000515	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—ovarian cancer	0.000167	0.000511	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—ovarian cancer	0.000167	0.00051	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000166	0.000507	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—ovarian cancer	0.000165	0.000505	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000162	0.000496	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—ovarian cancer	0.000162	0.000495	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—ovarian cancer	0.000161	0.000493	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—ovarian cancer	0.00016	0.000491	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—ovarian cancer	0.00016	0.00049	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—ovarian cancer	0.00016	0.00049	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—ovarian cancer	0.000154	0.000473	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000153	0.000469	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—ovarian cancer	0.000149	0.000456	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—ovarian cancer	0.000148	0.000454	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—ovarian cancer	0.000148	0.000454	CcSEcCtD
Maprotiline—Asthenia—Epirubicin—ovarian cancer	0.000145	0.000445	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—ovarian cancer	0.000143	0.000439	CcSEcCtD
Maprotiline—Imipramine—ABCB1—ovarian cancer	0.000143	0.0805	CrCbGaD
Maprotiline—Diarrhoea—Epirubicin—ovarian cancer	0.000139	0.000424	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—ovarian cancer	0.000135	0.000412	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—ovarian cancer	0.000134	0.00041	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—ovarian cancer	0.000133	0.000406	CcSEcCtD
Maprotiline—Vomiting—Epirubicin—ovarian cancer	0.000129	0.000394	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—ovarian cancer	0.000128	0.000393	CcSEcCtD
Maprotiline—Rash—Epirubicin—ovarian cancer	0.000128	0.000391	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—ovarian cancer	0.000128	0.000391	CcSEcCtD
Maprotiline—Headache—Epirubicin—ovarian cancer	0.000127	0.000389	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—ovarian cancer	0.000124	0.00038	CcSEcCtD
Maprotiline—Nausea—Epirubicin—ovarian cancer	0.00012	0.000369	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—ovarian cancer	0.000119	0.000365	CcSEcCtD
Maprotiline—Rash—Doxorubicin—ovarian cancer	0.000118	0.000362	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—ovarian cancer	0.000118	0.000362	CcSEcCtD
Maprotiline—Headache—Doxorubicin—ovarian cancer	0.000117	0.00036	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—ovarian cancer	0.000111	0.000341	CcSEcCtD
Maprotiline—CHRM5—Signaling Pathways—NRAS—ovarian cancer	6.24e-06	0.000142	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ABCB1—ovarian cancer	6.23e-06	0.000142	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	6.19e-06	0.000141	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CAV1—ovarian cancer	6.18e-06	0.000141	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	6.13e-06	0.00014	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—TYMS—ovarian cancer	6.12e-06	0.00014	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—ovarian cancer	6.07e-06	0.000138	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CASP3—ovarian cancer	6.07e-06	0.000138	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL2—ovarian cancer	6.06e-06	0.000138	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL6—ovarian cancer	6.03e-06	0.000138	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	6.01e-06	0.000137	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MAPK3—ovarian cancer	5.98e-06	0.000136	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—ovarian cancer	5.94e-06	0.000135	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MAPK1—ovarian cancer	5.94e-06	0.000135	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—ovarian cancer	5.94e-06	0.000135	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.91e-06	0.000135	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—ovarian cancer	5.91e-06	0.000135	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ERBB2—ovarian cancer	5.9e-06	0.000135	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	5.9e-06	0.000135	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—ovarian cancer	5.88e-06	0.000134	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—ovarian cancer	5.87e-06	0.000134	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—ovarian cancer	5.86e-06	0.000134	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	5.85e-06	0.000133	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	5.82e-06	0.000133	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MTOR—ovarian cancer	5.82e-06	0.000133	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CAV1—ovarian cancer	5.82e-06	0.000133	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—ovarian cancer	5.81e-06	0.000133	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	5.81e-06	0.000132	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—ovarian cancer	5.81e-06	0.000132	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ERBB2—ovarian cancer	5.8e-06	0.000132	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ERBB2—ovarian cancer	5.78e-06	0.000132	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ERBB2—ovarian cancer	5.76e-06	0.000131	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—ovarian cancer	5.74e-06	0.000131	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MTOR—ovarian cancer	5.73e-06	0.000131	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	5.73e-06	0.000131	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MTOR—ovarian cancer	5.72e-06	0.00013	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	5.72e-06	0.00013	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—ovarian cancer	5.7e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ERBB2—ovarian cancer	5.7e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MTOR—ovarian cancer	5.7e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	5.7e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MAPK1—ovarian cancer	5.69e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—ovarian cancer	5.69e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MTOR—ovarian cancer	5.68e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CB—ovarian cancer	5.68e-06	0.00013	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.63e-06	0.000128	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CB—ovarian cancer	5.63e-06	0.000128	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MTOR—ovarian cancer	5.63e-06	0.000128	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—ovarian cancer	5.61e-06	0.000128	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—ovarian cancer	5.6e-06	0.000128	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	5.56e-06	0.000127	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—HRAS—ovarian cancer	5.56e-06	0.000127	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	5.51e-06	0.000126	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—ovarian cancer	5.5e-06	0.000125	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	5.48e-06	0.000125	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	5.47e-06	0.000125	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	5.47e-06	0.000125	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—ovarian cancer	5.46e-06	0.000125	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—HRAS—ovarian cancer	5.46e-06	0.000124	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—ovarian cancer	5.46e-06	0.000124	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	5.44e-06	0.000124	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—HRAS—ovarian cancer	5.43e-06	0.000124	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	5.41e-06	0.000123	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	5.41e-06	0.000123	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	5.38e-06	0.000123	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	5.37e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—ovarian cancer	5.37e-06	0.000122	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	5.37e-06	0.000122	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—ovarian cancer	5.36e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	5.35e-06	0.000122	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—ovarian cancer	5.35e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1B—ovarian cancer	5.33e-06	0.000122	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—ovarian cancer	5.32e-06	0.000121	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	5.32e-06	0.000121	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	5.31e-06	0.000121	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.3e-06	0.000121	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	5.29e-06	0.000121	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	5.28e-06	0.00012	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—ovarian cancer	5.28e-06	0.00012	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—ovarian cancer	5.28e-06	0.00012	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—ovarian cancer	5.27e-06	0.00012	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—ovarian cancer	5.26e-06	0.00012	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—ovarian cancer	5.26e-06	0.00012	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—ovarian cancer	5.25e-06	0.00012	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—ovarian cancer	5.24e-06	0.00012	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—ovarian cancer	5.24e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—ovarian cancer	5.24e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—ovarian cancer	5.23e-06	0.000119	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—ovarian cancer	5.23e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	5.22e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—ovarian cancer	5.22e-06	0.000119	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—ovarian cancer	5.21e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—ovarian cancer	5.21e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—ovarian cancer	5.19e-06	0.000118	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—ovarian cancer	5.18e-06	0.000118	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—ovarian cancer	5.17e-06	0.000118	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	5.16e-06	0.000118	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—ovarian cancer	5.15e-06	0.000118	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	5.15e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—ovarian cancer	5.14e-06	0.000117	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—ovarian cancer	5.13e-06	0.000117	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—ovarian cancer	5.12e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—ovarian cancer	5.1e-06	0.000116	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—ovarian cancer	5.1e-06	0.000116	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NRAS—ovarian cancer	5.09e-06	0.000116	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—ovarian cancer	5.09e-06	0.000116	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	5.08e-06	0.000116	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	5.07e-06	0.000116	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—ovarian cancer	5.06e-06	0.000115	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	5.05e-06	0.000115	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HRAS—ovarian cancer	5.05e-06	0.000115	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—ovarian cancer	5.04e-06	0.000115	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CTNNB1—ovarian cancer	5.04e-06	0.000115	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—ovarian cancer	5.03e-06	0.000115	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	4.99e-06	0.000114	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—ovarian cancer	4.99e-06	0.000114	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—ovarian cancer	4.98e-06	0.000114	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—ovarian cancer	4.97e-06	0.000113	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—ovarian cancer	4.96e-06	0.000113	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—ovarian cancer	4.95e-06	0.000113	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.95e-06	0.000113	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—ovarian cancer	4.94e-06	0.000113	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—ovarian cancer	4.94e-06	0.000113	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	4.94e-06	0.000113	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAV1—ovarian cancer	4.93e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—ovarian cancer	4.93e-06	0.000112	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—ovarian cancer	4.91e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—ovarian cancer	4.91e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—ovarian cancer	4.89e-06	0.000112	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	4.87e-06	0.000111	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—ovarian cancer	4.86e-06	0.000111	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—ovarian cancer	4.83e-06	0.00011	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	4.83e-06	0.00011	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—ovarian cancer	4.82e-06	0.00011	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	4.81e-06	0.00011	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	4.79e-06	0.000109	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—ovarian cancer	4.77e-06	0.000109	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HRAS—ovarian cancer	4.77e-06	0.000109	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	4.74e-06	0.000108	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—ovarian cancer	4.74e-06	0.000108	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.71e-06	0.000107	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.66e-06	0.000106	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	4.64e-06	0.000106	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—ovarian cancer	4.64e-06	0.000106	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HRAS—ovarian cancer	4.57e-06	0.000104	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—ovarian cancer	4.56e-06	0.000104	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—ovarian cancer	4.55e-06	0.000104	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—ovarian cancer	4.5e-06	0.000103	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—ovarian cancer	4.49e-06	0.000102	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NRAS—ovarian cancer	4.49e-06	0.000102	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	4.47e-06	0.000102	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—ovarian cancer	4.46e-06	0.000102	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—ovarian cancer	4.46e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	4.45e-06	0.000101	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	4.44e-06	0.000101	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—ovarian cancer	4.43e-06	0.000101	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—ovarian cancer	4.42e-06	0.000101	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NRAS—ovarian cancer	4.42e-06	0.000101	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NRAS—ovarian cancer	4.41e-06	0.000101	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—ovarian cancer	4.41e-06	0.0001	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NRAS—ovarian cancer	4.39e-06	0.0001	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	4.39e-06	0.0001	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—ovarian cancer	4.39e-06	0.0001	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NRAS—ovarian cancer	4.38e-06	9.99e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—ovarian cancer	4.38e-06	9.99e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—ovarian cancer	4.37e-06	9.96e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—ovarian cancer	4.35e-06	9.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NRAS—ovarian cancer	4.34e-06	9.89e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.31e-06	9.83e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK3—ovarian cancer	4.3e-06	9.81e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	4.23e-06	9.65e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK3—ovarian cancer	4.22e-06	9.63e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—ovarian cancer	4.21e-06	9.6e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	4.21e-06	9.6e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	4.2e-06	9.57e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—ovarian cancer	4.18e-06	9.54e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	4.15e-06	9.47e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—ovarian cancer	4.14e-06	9.45e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—ovarian cancer	4.12e-06	9.38e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—ovarian cancer	4.11e-06	9.36e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—ovarian cancer	4.09e-06	9.33e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK1—ovarian cancer	4.09e-06	9.33e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—ovarian cancer	4.09e-06	9.33e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—ovarian cancer	4.08e-06	9.3e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.06e-06	9.26e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—ovarian cancer	4.04e-06	9.21e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—ovarian cancer	4.03e-06	9.19e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	4.03e-06	9.18e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—ovarian cancer	4.03e-06	9.18e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	4.02e-06	9.17e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK1—ovarian cancer	4.02e-06	9.16e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—ovarian cancer	4.02e-06	9.16e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	4e-06	9.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—ovarian cancer	4e-06	9.13e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	3.99e-06	9.1e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—ovarian cancer	3.99e-06	9.1e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	3.95e-06	9.01e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—ovarian cancer	3.95e-06	9.01e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.95e-06	9e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—ovarian cancer	3.89e-06	8.87e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—ovarian cancer	3.87e-06	8.81e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—ovarian cancer	3.8e-06	8.67e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—ovarian cancer	3.79e-06	8.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—ovarian cancer	3.78e-06	8.62e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—ovarian cancer	3.77e-06	8.6e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—ovarian cancer	3.73e-06	8.51e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—ovarian cancer	3.73e-06	8.5e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HRAS—ovarian cancer	3.72e-06	8.49e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—ovarian cancer	3.56e-06	8.12e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	3.55e-06	8.1e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—ovarian cancer	3.51e-06	8.01e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	3.49e-06	7.97e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	3.49e-06	7.95e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	3.48e-06	7.92e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	3.46e-06	7.9e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3.44e-06	7.85e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—ovarian cancer	3.44e-06	7.83e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	3.43e-06	7.82e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—ovarian cancer	3.38e-06	7.72e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—ovarian cancer	3.38e-06	7.71e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—ovarian cancer	3.37e-06	7.69e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—ovarian cancer	3.36e-06	7.67e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—ovarian cancer	3.35e-06	7.64e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—ovarian cancer	3.32e-06	7.57e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—ovarian cancer	3.29e-06	7.49e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HRAS—ovarian cancer	3.29e-06	7.49e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HRAS—ovarian cancer	3.23e-06	7.37e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HRAS—ovarian cancer	3.23e-06	7.35e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HRAS—ovarian cancer	3.22e-06	7.33e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HRAS—ovarian cancer	3.21e-06	7.31e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HRAS—ovarian cancer	3.17e-06	7.24e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—ovarian cancer	3.14e-06	7.17e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—ovarian cancer	3.09e-06	7.05e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—ovarian cancer	3.09e-06	7.04e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—ovarian cancer	3.08e-06	7.02e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—ovarian cancer	3.07e-06	6.99e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—ovarian cancer	3.04e-06	6.93e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—ovarian cancer	2.97e-06	6.78e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.9e-06	6.61e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.85e-06	6.51e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.85e-06	6.49e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—ovarian cancer	2.84e-06	6.47e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—ovarian cancer	2.83e-06	6.45e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—ovarian cancer	2.8e-06	6.39e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.63e-06	5.99e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.48e-06	5.65e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—ovarian cancer	2.15e-06	4.9e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.1e-06	4.78e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—ovarian cancer	2.02e-06	4.61e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—ovarian cancer	1.71e-06	3.91e-05	CbGpPWpGaD
